Germany's MorphoSys showcases pipeline and technology update at R&D day in London
At an R&D day in London, UK, yesterday, German biotechnology firm MorphoSys (MOR: GR) revealed significant recent developments and provided a full outlook on its partnered and proprietary drug pipeline as well as a comprehensive technology update, saying it has built one of the broadest antibody pipelines in the biotechnology industry with 12 clinical projects ongoing and a total of 76 distinct drug programs.
Among the announcements at the R&D day were:
Disclosure of multiple sclerosis as the second indication for the company’s lead development program MOR103, a fully-human HuCAL antibody targeting GM-CSF. The decision is based on a compelling scientific rationale and promising preclinical data. MorphoSys said it expects to start a Phase Ib trial in multiple sclerosis with MOR103 in second-half 2011.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze